Osiris to be acquired by British medical device company for $660.5M

By | Uncategorized | No Comments

A British medical device manufacturing company plans to acquire Osiris Therapeutics Inc. for $660.5 million.

Smith & Nephew plc will pay $19 per share for Osiris in the all-cash deal expected to close in the second quarter. Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud. Osiris develops products for wound care, orthopedics and sports medicine using stem cells.

London-based Smith & Nephew is paying a 37 percent premium from the 90-day weighted average stock price. Shares of Osiris were up less than 1 percent in trading Tuesday morning to $19.03.

Peter Friedl, chairman and co-founder of Osiris, said in a statement the deal is a “very good outcome” for shareholders and will help “take the business to the next level.”

“I am immensely proud of the business we have built from our research into advanced regenerative technologies,” Friedl said. “I believe Smith & Nephew is the right home for Osiris and will allow our products to reach more customers, helping to restore quality of life for more patients.”

All 360 of Osiris’ employees are expected to join Smith & Nephew upon completion of the deal.

Click here to read more via the Baltimore Business Journal.

TEDCO Generates $1.6 Billion in Economic Benefits to the State of Maryland and Supports 7,746 Maryland Jobs, According to New Independent Study

By | News | No Comments

COLUMBIA, Md. (March 6, 2019)— The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced today the findings of an independent economic impact study detailing the economic development contributions of TEDCO’s five core programs to the state of Maryland.

Conducted by Richard Clinch of the University of Baltimore’s Jacob France Institute and Mitch Horowitz of TEConomy Partners (JFI-TEConomy), the study found that TEDCO is a significant economic driving force, supporting 7,746 Maryland jobs and more than $1.6 billion in statewide economic activity in 2018.

The study says TEDCO has generated significant economic and fiscal returns to the state. Reviewing the change from 2015 to 2018, TEDCO’s economic impact included job creations from 4,358 in 2015 to 7,746 in 2018. TEDCO’s total economic impact has also seen a significant increase from $1B in 2015 to $1.6B in 2018. The jobs supported by these companies earn $600.1 million in labor income and generate estimated state and local government revenues of $66.6 million, according to the study.

By 2023, the study projects TEDCO’s economic impact will increase substantially to $2.4B and will support a total of 11,812 jobs.

Click here to read more via TEDCO

These 3 tech investors are the most active in the DMV: report

By | Uncategorized | No Comments

Three investment firms topped the list of local tech investors in the DMV region according to CB Insights‘ report, The United States of Venture Capital.

The report looks at the most active venture capital firms in each U.S. state based on unique tech portfolio investments. Chevy Chase, Md.-based New Enterprise Associates (NEA) was listed as the most active tech investor in the District while CIT GAP Funds topped the list in Virginia and TCP Venture Capital in Maryland. The report looked at their unique tech investments between 2014 and Jan. 24, 2019.

CB Insights said it excluded debt deals and only considered venture capital, corporate venture capital, super angel and growth equity firms. In the case of a tie, CB Insights used recency of deals, overall deal activity and investor quality. NEA was the only firm to lead more than one state with the most investments in D.C. and New Jersey. CB Insights’ last conducted this report in May 2017 and since then, there has been 21 changes in the top investor slots. According to CB Insights, Fortify Ventures led the way in D.C back in May 2017.

Click here to read more via Technic.ly DC

Behrman Capital Makes Significant Investment in Emmes

By | News | No Comments

ROCKVILLE, Md.March 4, 2019 /PRNewswire/ — Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company.  The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.

Behrman Capital has a 25-year track record of successfully investing in growing healthcare services companies, adding resources and professional services to help them innovate and expand.

“This is a substantial and exciting milestone in our evolution,” said Dr. Anne Lindblad, president and chief executive officer of Emmes.  “The Emmes name will continue, as will our vision, mission, leadership, and focus on advancing human health.  We will benefit from Behrman’s investment, expertise and relationships.  We believe this investment will allow us to provide employees even greater opportunities as we continue to build and grow.

“Our government work is and will remain core, and we plan to accelerate our efforts on the non-government side,” she added.

According to Grant Behrman, managing partner of Behrman Capital, “Emmes has world class talent and an outstanding reputation in clinical research.  It has built an especially strong legacy in the government sector and, in particular, at the National Institutes of Health.  Our role is to invest in the company’s future growth, from employee development to expanded offerings to current and prospective clients.”

Click here to read the entire release vis PR Newswire

State Department awards Emergent BioSolutions contract for chemical warfare countermeasures

By | News | No Comments

Emergent BioSolutions announced today that the company has signed a deal with the U.S. Department of State to establish a supply chain for certain medical countermeasures that address chemical warfare agents.

The five-year, indefinite-delivery, indefinite-quantity (IDIQ) contract includes five additional one-year option periods. The total contract value is worth a minimum of $7 million to a maximum of $100 million over the contract’s period of performance.

As part of the deal, Emergent will supply the State Department with the Trobigard atropine sulfate/obidoxime chloride auto-injector, a drug-device for emergency use in the event of nerve agent or organophosphate poisoning, and RSDL (Reactive Skin Decontamination Lotion Kit), which is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin. Under this contract, Emergent will maintain the capability to manufacture and deliver the Trobigard auto-injector, RSDL, and auto-injector training devices.

“Emergent is pleased with this follow-on opportunity to meet the U.S. government’s need for medical countermeasures that enhance the security of U.S. diplomats and other Chief of Mission personnel engaged in high-risk environments worldwide,” Doug White, senior vice president and head of the devices business unit at Emergent BioSolutions, said. “Our mission – to protect and enhance life – has been at the core of our 20-year history of partnering with governments. We look forward to successfully completing deliveries of our Trobigard auto-injector under our 2017 contract and to our continued partnership with the State Department as we expand our portfolio of solutions to address existing and emerging chemical warfare agents for the long-term.”

Click here to read more via homelandprepnews.com

Van Hollen: Despite Trump, NIH Significantly ‘Better Off’ In Terms of Funding

By | News | No Comments

Funding for the Bethesda-based National Institutes of Health is up by 14 percent during the two years that President Donald Trump has been in the White House — but it’s despite and not because of the president, according to Maryland Sen. Chris Van Hollen.

“The short answer is NIH is better off – but not because of Trump at all,” Van Hollen, a Democrat, said during a wide-ranging telephone interview with Bethesda Beat, in which he reviewed highlights of his first two years in the Senate and laid out his legislative priorities for the next two. “In fact, when Trump came in, in his first budget year, he proposed a pretty deep cut in NIH funding.”

Van Hollen said the Senate Appropriations Committee, on which he serves, had played a key role in the “significant increase” in funding for NIH, where the annual budget has jumped from $34.3 billion when Trump took office in January 2017 to $39.1 billion for the 2019 fiscal year.

The current NIH budget is $4.3 billion more than Trump originally proposed.

On top of a nearly 9 percent hike for fiscal 2018, NIH funding went up another 5 percent for 2019 – an increase consistent with that proposed by the Senate Appropriations Committee and backed by the full Senate.

“I fought very hard to get on [the Appropriations Committee],” said Van Hollen, only the second Montgomery County resident elected to represent Maryland in the Senate. “It’s very rare that a new member of the Senate gets on that committee … And we had a lot of success in fighting for important Maryland and national priorities.”

Read more via Bethesda Magazine

Danaher acquiring GE biopharma business for $21.4B

By | News | No Comments

D.C.-based Danaher Corp. is acquiring Boston-based General Electric Co.’s biopharma business for $21.4 billion in an all-cash deal announced Monday.

GE Biopharma, part of GE Life Sciences, supports research, development and manufacturing of biopharmaceutical drugs. The unit, consisting of instruments, technologies and consumables, is expected to generate roughly $3.2 billion in 2019 revenue, according to a release.

The transaction’s net price comes to about $20 billion with tax benefits, 17-times GE Biopharma’s expected earnings before interest, tax, depreciation and amortization. Danaher, a conglomerate of industrial and commercial manufacturers, plans to finance the deal with about $3 billion of proceeds from an equity offering, along with cash on-hand and other sources.

It’s expected to close in the fourth quarter, and is not subject to a shareholder vote or financing condition.

Danaher was formerly led by current GE Chairman and CEO Larry Culp.

Under the deal, the unit will exist as a standalone operating company within Danaher’s $6.5 billion life sciences portfolio. It will function alongside its other businesses including Pall, Beckman Coulter Life Sciences, SCIEX, Leica Microsystems, Molecular Devices, Phenomenex and IDT.

“This acquisition will bring a talented and passionate team as well as a highly innovative, industry-leading product suite to our Life Sciences portfolio, providing an excellent complement to our current biologics workflow solutions.,” said Danaher President and CEO Thomas Joyce Jr. in a statement. The addition is also expected to advance the company’s growth and innovation strategy in the life science market, he said.

Read more via the Washington Business Journal

Galen Robotics Wins BioHealth Capital Region 3rd Annual Crab Trap Competition

By | News | No Comments

Galen Robotics, a Johns Hopkins University spinout, was chosen from five finalists as the company with the most commercial potential by judges at the 3rd Annual Crab Trap Competition. This year’s judges included industry leaders Amgen’s Bethany Mancilla, AstraZeneca’s Shaun Grady, Blu Venture’s Dr. Paul Silber, J.P. Morgan’sJohn T. Rubin, New Enterprise Associates’ Sara Nayeem, Roche’s Robert Silverman, and Sands Capital Ventures’ Stephen Zachary. They were impressed with a presentation by Lead Hardware Engineer, Yunus Sevimli, on Galen Robotics’ low-cost, compact, and intuitive to use novel microsurgical robotic platform designed to assist surgeons with minimally-invasive applications in otolaryngology, neurosurgery and similar critical fields. Galen Robotics is the third Johns Hopkins University spinout to win this competition following  LifeSprout (2017) and Sonavex (2016).

Strong presentations also were made by the other finalists–AlgometRx, Cellth Systems, Renalert, and Reveragen Biopharma—whose technologies originated at Children’s National Medical Center, the University of Maryland, and Johns Hopkins University.

View Original Article »

Join our Mailing List